Theraflu Extra Lemon powder for oral solution with lemon flavour

Land: Armenia

Språk: engelsk

Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktiv ingrediens:

paracetamol, phenylephrine (phenylephrine hydrochloride), pheniramine (pheniramine maleate)

Tilgjengelig fra:

Delpharm Orleans

ATC-kode:

N02BE51

INN (International Name):

paracetamol, phenylephrine (phenylephrine hydrochloride), pheniramine (pheniramine maleate)

Dosering :

650mg+ 10mg+ 20mg

Legemiddelform:

powder for oral solution with lemon flavour

Enheter i pakken:

(10) sachets 15g

Resept typen:

OTC

Autorisasjon status:

Registered

Autorisasjon dato:

2020-06-30

Preparatomtale

Property of GSK Consumer Healthcare SA
THERAFLU
EXTRA LEMON
Powder in Sachets
Actives substances
Paracetamol 650mg; Pheniramine maleate 20mg;
Phenylephrine hydrochloride 10mg
SUMMARY OF PRODUCT CHARACTERISTICS
Document status:
FINAL
Release date:
17 Apr 2020
Number of pages:
12
Property of GSK Consumer Healthcare SA
TABLE OF CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
.........................................................................
3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
.............................................. 3
3.
PHARMACEUTICAL FORM
..............................................................................................
3
4.
CLINICAL PARTICULARS
.................................................................................................
3
4.1 THERAPEUTIC INDICATIONS
................................................................................................
3
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
................................................................... 3
4.3.
CONTRAINDICATIONS
.......................................................................................................
4
4.4.
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
.................................................... 4
4.5.
INTERACTIONS WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION ......... 5
4.6.
PREGNANCY AND LACTATION
.............................................................................................
6
4.7.
EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
............................................................ 6
4.8.
UNDESIRABLE EFFECTS
.......................................................................................................6
4.9.
OVERDOSE
.......................................................................................................................
9
5.
PHARMACOLOGICAL PROPERTIES
..............................................................................
10
5.1.
PHARMACODYNAMIC PROPERTIES
.................................................